Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease by Posovszky, Carsten et al.
Posovszky et al. BMC Gastroenterology 2013, 13:77
http://www.biomedcentral.com/1471-230X/13/77
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
53
05
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7RESEARCH ARTICLE Open AccessAge-of-onset-dependent influence of NOD2 gene
variants on disease behaviour and treatment
in Crohn’s disease
Carsten Posovszky1*, Veronika Pfalzer1, Georgia Lahr1, Jan Hendrik Niess2, Jochen Klaus2, Benjamin Mayer4,
Klaus-Michael Debatin1 and Georg BT von Boyen3Abstract
Background: Influence of genetic variants in the NOD2 gene may play a more important role in disease activity,
behaviour and treatment of pediatric- than adult-onset Crohn’s disease (CD).
Methods: 85 pediatric- and 117 adult-onset CD patients were tested for the three main NOD2 CD-associated
variants (p.R702W, p.G908R and p.10007fs) and clinical data of at least two years of follow-up were compared
regarding disease behaviour and activity, response to therapy and bone mineral density (BMD).
Results: Chronic active and moderate to severe course of CD is associated in patients with pediatric-onset
(p=0.0001) and NOD2 variant alleles (p=0.0001). In pediatric-onset CD the average PCDAI-Score was significantly
higher in patients carrying NOD2 variants (p=0.0008). In addition, underweight during course of the disease
(p=0.012) was associated with NOD2 variants. Interestingly, osteoporosis was found more frequently in patients
carrying NOD2 variant alleles (p=0.033), especially in pediatric-onset CD patients with homozygous NOD2 variants
(p=0.037). Accordingly, low BMD in pediatric-onset CD is associated with a higher PCDAI (p=0.0092), chronic active
disease (p=0.0148), underweight at diagnosis (p=0.0271) and during follow-up (p=0.0109). Furthermore, pediatric-onset
CD patients with NOD2 variants are more frequently steroid-dependent or refractory (p=0.048) and need long-term
immunosuppressive therapy (p=0.0213).
Conclusions: These data suggests that the presence of any of the main NOD2 variants in CD is associated with
osteoporosis and an age of onset dependent influence towards underweight, higher disease activity and a more
intensive immunosuppressive therapy. This observation supports the idea for an early intensive treatment strategy in
children and adolescent CD patients with NOD2 gene variants.
Keywords: Crohn’s disease, NOD2, CARD 15, Osteoporosis, Pediatric-onsetBackground
Inflammatory bowel disease (IBD) is characterized by
chronic inflammation of the gastrointestinal tract and
can occur at any age. Crohn’s disease (CD), ulcerative
colitis (UC) and indeterminated colitis are defined
according to the clinical, endoscopic, radiological and
histopathological features. IBD is a multifactorial disease
caused by genetic, bacterial, nutritional, and immunological
factors. There is clear evidence for a strong genetic* Correspondence: carsten.posovszky@uniklinik-ulm.de
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reproduction in any medium, provided the orinfluence in the pathogenesis of IBD, especially in CD,
coming from twin studies [1] with disease concordance
up to 50% for monozygotic CD twins. In addition,
pediatric-onset CD is characterized by distinct phenotypic
differences compared to adult-onset suggesting that a
genetic susceptibility may play an important role [2].
Polymorphisms in the leucine-rich repeats (LRR) region of
the NOD2/CARD15 gene were identified as independent
risk factors for CD in Caucasians [3,4], which varies
depending on the number of mutations from a 2 to
4-fold increased risk with 1 of the 3 major alleles to 40-fold
increase in homozygous or compound heterozygous
carriers [5]. The three major polymorphisms in the codingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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R702W, p.G908R, and p.L1007fs. The NOD2 gene is
involved in the innate immune response by recognizing
muramyl dipeptide of intracellular bacterial lipopolysac-
charides and activating nuclear factor κB pathways [6].
NOD2 is mainly expressed in Paneth cells in the small
bowel and is involved in the innate immune response to
bacterial pathogens [7]. Thus variant NOD2 alleles are
associated with reduced defensin expression in response
to bacteria [8]. Children have shorter environmental
exposure and therefore genetic factors such as NOD2
variants may have a greater influence in the etiology
and severity of CD [9]. Disease behaviour may change over
time, thus long-term follow-up data on pediatric-onset
disease are needed [10]. Indeed, the few studies analyzing
genotype-phenotype in pediatric-onset CD with longer
observation time revealed associations of NOD2 variants
with disease severity and risk for surgery [11,12].
Children and adolescents suffering from IBD are at
risk of developing osteoporosis. The prevalence of severe
demineralization in children and in adults ranges from
4.35% to 42% [13]. The pathogenesis of osteoporosis in
CD is not completely understood. Bone mineral density
(BMD) is influenced by several factors including chronic
or recurrent corticosteroid use, malnutrition or malab-
sorption, low body mass index (BMI), hypogonadism,
immobilisation, vitamin D deficiency [14]. Together these
factors result in low turnover bone loss. However,
also inflammation may significantly contribute to a
high-turnover mineral bone loss in CD [14-16].
Osteoclastogenesis and bone resorption is driven by
inflammatory mediators such as tumor necrosis factor
(TNF) α, Interleukin (IL)-1β and Il-6 in synergy with
receptor activator of nuclear factor kappa B ligand
(RANKL). RANKL is released by activated T-cells and
binds RANK on osteoclastic precursors and thereby
induce and activate osteoclasts [17]. Thus a chronic
inflammatory state, such as the gut in CD patients, in
addition affects bone remodelling and contributes to
high turn-over mineral bone loss. The influence of
NOD2 genotype on osteoporosis in CD has not been
studied yet.
We therefore wished to investigate the potential
relationship between the three major NOD2/CARD15
variants in a well characterized, long term follow up
dataset of Crohn patients with pediatric- and adult-onset
and inflammatory phenotype, response to therapy and
lower bone mineral density.
Methods
Study population and disease phenotype
The single center study, approved by the Ethics committee
Board of the Ulm University, adheres to the ethical princi-
ples of the Helsinki Declaration. 202 patients wererecruited in the department of pediatrics and adolescent
medicine as well as in the department of internal medicine
at the Medical University Center Ulm. The patients or
their parents gave written informed consent to participate
in the study.
The patient’s diagnosis based on clinical, radiological,
endoscopic and histopathologic findings, and presence
of disease for at least 2 years from diagnosis with follow-up.
Patients with uncertain diagnosis or unclassified colonic
inflammatory bowel disease were excluded. The pediatric-
onset cohort included patients with age of onset until the
age of 18 and final diagnosis until the age of 19. Parame-
ters including age of diagnosis and duration of disease,
sex, disease localization, disease behaviour, family history
of IBD, body weight and length, body mass index
(BMI), extraintestinal involvement, bone mineral density,
medical and surgical therapy and disease activity including
hospitalization were updated, analyzed and classified
according to the Montreal classification. Disease location
and behaviour was defined as involvement at any time
during disease. Underweight was defined as BMI below
10th percentile for age. Growth failure was defined as
inappropriate growth velocity for age and short stature
was defined as height below the 3rd percentile for age on a
growth chart. Disease activity was calculated based on
PCDAI for children with Crohn’s disease [18] or CDAI for
adults during regular or emergency visits and given as
mean value. An average PCDAI/CDAI score above ≥ 10/
150 was defined as chronic active and ≥ 30/220 as
moderate to severe disease. In children, a hospitalization
of more than two weeks per year due to CD was given to
describe disease activity and the percentage of severe ill
patients.
Bone mineral density measurement
Bone mineral density of the lumbar spine (L2-L4) was
evaluated using dual-energy X-ray absorptiometry (DEXA)
in patients with inflammatory bowel disease using a
Hologic QDR 1000 and expressed as grams per square
centimetre. Osteoporosis was defined in children as less
than two standard deviations (SD) of BMD adjusted to an
age matched population (Z-score) [19] and in adults as
BMD compared to a young normal reference mean below
2.5 SD (T-score) [20].
Therapy modalities
The treatment was according to the German guidelines
[21] and blinded to the genotype data. Patients received
prednisolon (2 mg/kg up to 100 mg/d), budenoside (9 mg/
d), azathioprine (AZA) (2.0-2.5 mg/kg/d), 6-mercaptopurin
(6-MP) (1–1.5 mg/kg/d), methotrexate (MTX) (15 mg/m2/
week s.c.), infliximab, a chimeric monoclonal antibody to
TNFα (5 mg/kg at weeks 0, 2, 6 and every 8 weeks), or
adalimumab, a humanized monoclonal antibody to TNFα
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adults or dose-adjusted for children 24 mg/m2 and
adapted for through level). Patients with chronic active
disease who did not respond to steroid therapy or relapsed
within the first 4 weeks were defined as steroid-dependent
or steroid-refractory respectively. These patients were
then switched to an immunosuppressive long-term
therapy with AZA, 6-MP, MTX or TNF-α antagonists.
Patients with pediatric-onset received TNF-α antagonists
as second line therapy if enteral therapy, AZA, 6-MP or
MTX failed to induce stable remission, withdrawal of
steroid treatment was impossible and surgical treatment
was not reasonable or not accepted by the patients or
their guardians.
DNA extraction and genotyping of NOD2 variants
Genotyping of the three main NOD2 variants p.R702W
(rs2066844, exon 4), p.G908R (rs2066847, exon 8), and
p.1007fs (rs20066847, exon 11) were performed in 85
pediatric and 117 adult CD patients of Caucasian origin.
Therefore peripheral blood mononuclear cells (PBMCs)
of the patients were obtained. Genomic deoxyribonucleic
acid (DNA) was extracted from PBMCs using standard
methods using QIAmp Flexi Gen DNA Kit (Qiagen,
Hilden, Germany). Exons 4, 8 and 11 of the NOD2 gene
were individually amplified by polymerase chain reaction
(PCR) analysis using standard methods. PCR-samples
were sequenced using the CEQ Quick Start Kit on a GeXP
Genetic Analysis System (Beckman Coulter, Krefeld) and
compared with wild-type NOD2-gene sequence.
Statistical analysis
Absolute and relative frequencies were used to describe
qualitative variables descriptively, and mean with standard
deviation as well as median with interquartile range for
continuous variables. Differences between frequencies of
qualitative characteristics in CD patients carrying NOD2
variants or wild-type were compared using chi-square
test or Fishers exact test, respectively. Mann–Whitney
or Kruskal-Wallis tests were applied to compare
medians and T-test to compare means, respectively. A
p value ≤ 0.05 was considered to be significant.
Descriptive statistics for quantitative values were given
as median and interquartile range in box plot diagrams
using Graphpad Prism software. All statistical tests are
interpreted explorative. To adjust for possible confounding,
multivariate regression analyses have been conducted in
the course of a sensitivity analysis.
Results
Demographic and disease characteristics of the study
population
Data regarding NOD2 genotype, age of onset, average
disease duration, disease location and behaviour wereobtained from two hundred and two German patients
with adequate follow-up and are presented in Table 1
according to the age of onset of CD. NOD2 variant
alleles were found in 37 out of 85 pediatric- (44%) and
47 out of 117 adult- (40%) onset CD patients (Table 1).
No significant differences were noted in the distribution
of the three main NOD2 allele variants (data not shown),
however the presence of two variant alleles trend to be
higher in pediatric-onset than in adult-onset patients
(p=0.12) (Table 1). The mean follow-up was around 11
years in the pediatric-onset group and 16 years in the
adult-onset group. Interestingly, the prevalence of IBD
in first- or second-degree relatives of CD patients is
statistically more frequent in adult-onset CD patients
with NOD2 variants in contrast to NOD2 wild-type (29%
versus 6%; p=0.0023) but not in the pediatric-onset CD
patients (Figure 1).
Carrying at least one NOD2 variant allele is associated
with an ileocolonic (L3) localization (p=0.048) in the
pediatric- and a trend to an ileal involvement alone in
the adult-onset CD patients (38% versus 21%; p=0.06),
while pediatric-onset NOD2 wild-type patients more
frequently had a colonic involvement alone (p=0.048).
The influence of NOD2 variants towards complicated
disease behaviour (B2 or B3) is more pronounced in
patients with pediatric-onset CD (p=0.026). Stricturing
disease behaviour (B2) is significantly associated with
NOD2 variant alleles in pediatric-onset (p=0.005) and
adult-onset CD Patients (p=0.051) (Table 1).Pediatric-onset CD patients carrying NOD2 variant alleles
display a higher disease activity and underweight
There is no significant influence of the main NOD2
variants in patients with CD towards extraintestinal
manifestation, need for surgery or complications (Figure 1).
However, we found chronic active or high active course
of disease in CD patients associated with pediatric-onset
of disease (p=0.0001) and any of the main NOD2 variant
alleles (p=0.0001). The average PCDAI-Score over time
was significantly higher in pediatric-onset CD patients
with at least one NOD2 variant than two wild-type al-
leles (23.2 versus 14.1; p=0.0008) (Figure 2A), and a
chronic active (PCDAI≥10 or CDAI≥150; p=0.017) or
moderate to severe course (PCDAI ≥ 30 or CDAI≥220;
p=0.027) of disease significantly more frequent. How-
ever, in the adult-onset group disease activity and moder-
ate to severe course measured by CDAI was independent
of the NOD2 genotype (Figure 2B).
Pediatric-onset CD is associated with growth delay
at diagnosis and during the first year after diagnosis,
however only underweight during course of disease is
associated with patients carrying NOD2 variant alleles
(p=0.012; Figure 3).
Table 1 Characteristics of 202 patients with pediatric- and adult-onset Crohn’s disease according to the Montreal
classification [22] regarding NOD2 genotype at latest follow-up
Patients Pediatric-onset CD (≤18 y) Adult-onset CD (>18 y)
n=202 n=85 n=117
NOD2 genotype Main variants Wild-type p-value Main variants Wild-type p-value
Number: n (%) 37 (44%) 48 (56%) 47 (40%) 70 (60%) 0.67
1 variant allele 23 (27%) 37 (32%)
2 variant alleles 14 (16%) 10 (9%) 0.12
homozygous variant alleles 7 (8%) 3 (3%) 0.099
Gender: female/male (%) 57/43 38/62 0.08 51/49 59/41 0.39
Age: year
mean/SD 26/13.0 22.7/12.6 0.26 47.3/14.3 46.5/13.4 0.67
median/interquartile range 22/17-35 20/15-26 0.18 46/36-62 45/36-54 0.78
average disease duration/SD 12.8/11.2 11.3/10.5 0.63 16.2/11.3 16.5/10.3 0.89
Age at diagnosis: year
mean/SD 13.9/3.3 12.1/4.9 0.07 31.5/10.0 30.5/10.6 0.49
median/interquartile range 15.0/12-17 13.0/9-17 0.18 27/23-33 29/24-38 0.32
Localization: n (%)
L1 ileal 9 (24%) 12 (25%) 1.0 18 (38%) 14 (21%) 0.058
L2 colonic 3 (8%) 13 (27%) 0.048* 4 (8%) 11 (16%) 0.27
L3 ileocolonic 26 (68%) 23 (48%) 0.048* 25 (53%) 41 (61%) 0.35
L4 isolated upper disease 0 (0%) 0 (0%) 1.0 0 (0%) 1 (1%) 1.0
Upper GI involvement 12 (32%) 16 (33%) 1.0 1 (2%) 7 (10%) 0.14
Behaviour: n (%)
B1 non-stricturing/penetrating 16 (43%) 33 (69%) 0.026* 16 (35%) 28 (41%) 0.53
B2 stricturing 15 (41%) 6 (13%) 0.005* 22 (48%) 20 (29%) 0.051
B3 penetrating intern 6 (16%) 3 (6%) 0.16 12 (26%) 11 (16%) 0.23
B3p penetrating perianal 7 (19%) 7 (15%) 0.76 8 (17%) 19 (28%) 0.27
* indicates p value ≤ 0.05 considered to be significant.
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inflammatory course of disease and underweight
BMD measured by DEXA was available for 77 pediatric-
and 91 adult-onset CD patients. Osteoporosis was
associated with patients carrying NOD2 variant alleles
(p=0.033) and pediatric-onset of CD (p=0.022). Multivariate
analysis demonstrated a 2.4 times increased risk for
osteoporosis in CD patients carrying any NOD2 variant
allele (p=0.02). There was also a suggestive trend for CD
patients with NOD2 variant alleles and pediatric-onset
towards osteoporosis (p=0.12, Figure 1; and by multivariate
analysis p=0.07) and low BMD (Z-score below −1 p=0.10;
Table 2). Especially pediatric onset CD patients with
homozygous NOD2 variant alleles are prone to osteopor-
osis and osteopenia (p=0.037; Table 2) and lower Z-scores
respectively (p=0.033). We further evaluated the impact of
factors independent of the NOD2 genotype influencing
BMD. 46 out of 77 patients had a low BMD (Z-scorebelow −1) thereof 23 (30%) suffered from osteoporosis
(Z-score below −2.0) and 23 (30%) from osteopenia,
only 31 (40%) had normal BMD (Table 2). The average
disease duration was around 12 years in the low and
normal BMD group. Osteoporosis at diagnosis of CD
or in the follow-up was not associated with surgery,
complications, extraintestinal manifestation or ileal or
ileocolonic involvement (Table 2 and data not shown).
However, patients with low BMD Z-scores had a signifi-
cantly higher PCDAI-score (p=0.0092) (Figure 4). A
multivariate regression model demonstrated that the
PCDAI-score is 5.8 points higher in patients with low
BMD than normal BMD, whereas this effect is adjusted
for steroid dependent or refractory course of disease
and underweight (p=0.03). In addition, underweight at
diagnosis (p=0.045) and after 1year of follow up (p=0.011)
but not short stature was significant associated with
low BMD (Table 2). The need for immunosuppressive
A
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B
p=0.84
p=0.84 p=0.34
p=0.52
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Pediatric-onset CD
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Figure 1 Effect of NOD2 gene variants in CD patients on disease
behaviour. CD patients with pediatric-onset (A) or adult-onset (B) of
disease with NOD2 variant (grey bars) or NOD2 wild-type alleles (white
bars) are compared regarding family history (FA) of IBD, extraintestinal
manifestation (EIM), surgery or complication because of CD, and
osteoporosis. BMD was available from 169 out of 202 patients.
Differences were compared using chi-square or Fishers exact test,
respectively. A p-value below ≤0.05 was considered to be significant.
Figure 2 Effect of NOD2 variants on PCDAI and CDAI Score in
pediatric- and adult-onset CD patients. CD patients with
pediatric-onset (A) and adult-onset (B) are compared regarding
NOD2 variant (grey bars) or NOD2 wild-type alleles (white bars) and
their average PCDAI or CDAI Score. The median (lines within the
boxes), the interquartile range (boxes) and the whole range are
given. Differences were compared using unpaired, two sided
Mann–Whitney test. A p-value below ≤0.05 was considered to
be significant.
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(MTX) was associated with low BMD (p=0.016) and
there was a trend to steroid-refractory or dependent course
(p=0.1) or anti-TNFα therapy (p=0.09). Interestingly,
57% of the patients with low BMD were steroid- or
immunosuppressiva naïve at the time of the first
measurement (data not shown).
Influence of NOD2 genotype on therapy regarding age at
diagnosis of CD
Comparing therapy and NOD2 genotype revealed divergent
trends between pediatric- and adult onset CD. Steroid
dependent or refractory course of disease was more
frequent in pediatric-onset CD patients with NOD2
variants (p=0.048) (Figure 5). In addition, the use of
long-term immunosuppressive drugs such as anti-
TNFα agents; azathioprine or methotrexate trend to be
higher in patients with NOD2 variant alleles and pediatric
onset in contrast to adult-onset CD (Figure 5). This is also
confirmed by analyzing the relationship between age of
diagnosis, response to therapy and NOD2 genotype. A
significant age dependent difference towards therapy wasonly found in CD patients carrying NOD2 variants. CD
patients carrying at least one NOD2 variant allele and
being young at diagnosis (median age below 20 years)
are at risk for steroid dependent or refractory course of
disease (p=0.0022), long-term immunosuppressive therapy
with AZA or MTX (p=0.0426) and the use of anti-TNFα
agents (p=0.0004) (Additional file 1: Figure S1). In
addition, carrying a NOD2 variant allele is associated with
a 3.1 increased risk for steroid dependent or refractory
course of disease (p=0.02).
Figure 3 Effect of NOD2 variants on underweight, growth
failure, short stature and hospitalization in pediatric-onset CD
patients. Pediatric-onset CD patients with NOD2 variant (grey bars)
or NOD2 wild-type alleles (white bars) were compared regarding
underweight at diagnosis and during follow up, growth failure, short
stature and hospitalization for more than two weeks per year. BMI at
diagnosis and growth delay at one-year follow-up was available
from 51 out of 85 patients (39% NOD2 variant allele carriers).
Differences were compared using chi-square or Fishers exact test,
respectively. A p-value below ≤0.05 was considered to be significant.
Table 2 Characteristics of 77 Crohn patients with
pediatric-onset according to the Montreal classification
regarding BMD adjusted for age
Pediatric-onset CD patients Low BMD Normal BMD
p-valueZ-score<−1 Z-score ≥−1
n=77 n=46 n=31
% 60% 40%
NOD2 variant n (%) 24 (52%) 10 (32%) p=0.10
One variant allele 17 5 p=0.061
Two variant alleles 7 5 p=0.75
Homozygous variant alleles 7 0 p=0.037*
Gender: female/male in % 45/55 48/52 p=0.89
Age: y
mean/SD 25/12.8 24/13.9 p=0.62
median/interquartile range 21/17-30 19/15-29 p=0.29
average disease duration/SD 12.2/11.6 11.6/10.8 p=0.84
Age at diagnosis: y
mean/SD 13/3.6 12/5.1 p=0.33
median/interquartile range 14/11-16 13/10-17 p=0.69
Localization: n (%)
L1 ileal 8 (17%) 9 (29%) p=0.27
L2 colonic 8 (17%) 6 (19%) p=1.0
L3 ileocolonic 30 (65%) 16 (52%) p=0.25
L4 isolated upper disease 0 (0%) 0 (0%) p=1.0
Upper GI involvement 15 (33%) 13 (42%) p=0.47
Behaviour: n (%)
B1 non-stricturing/penetrating 27 (59%) 20 (65%) p=0.64
B2 stricturing 11 (23%) 6 (19%) p=0.78
B3 penetrating intern 6 (13%) 3 (10%) p=0.73
B3p penetrating perianal 9 (19%) 3 (10%) p=0.34
Underweight at diagnosis 14/27 (52%) 5/22 (32%) p=0.0453*
Underweight in 1y follow-up 14 (30%) 2 (6%) p=0.0113*
Short stature 5 (11%) 1 (3%) p=0.39
Treatment: n (%)
Steroid dependent/refractory 23 (50%) 9 (29%) p=0.10
Azathioprine / MTX 35 (76%) 15 (48%) p=0.016*
Anti-TNFα-antibody 20 (44%) 7 (26%) p=0.09
* indicates p value ≤ 0.05 considered to be significant.
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Evaluation of disease behaviour by genotype is complex
and may change throughout the course of disease.
Dissecting pediatric- and adult-onset CD represents a
model to identify further associations between NOD2
gene variants and phenotypes and may help in selecting
individual treatment regimes for patients with CD. We
here demonstrate greater influence of NOD2 variants in
pediatric-onset CD patients towards higher disease activity,
risk for underweight, osteoporosis and more intensive
immunosuppressive therapy. This is the first study
identifying an influence of NOD2 variant alleles in
patients with CD on osteoporosis and an age of onset
dependent risk for steroid dependent or refractory course,
long-term use of immunosuppressive drugs.
In this retrospective single center study in a tertiary
center we report a high prevalence of CD patients carrying
at least one NOD2 variant allele with 44% in the pediatric-
and 42% in adult-onset CD similar to other European
pediatric multicenter cohort studies with a prevalence of
35 up to 45.6% [12,23,24]. In addition, the presence of two
NOD2 mutant alleles was found more frequent in the
pediatric-onset CD patients as reported by others [23,25]
and may predict complicated disease [26].
Growth retardation is a frequent specific feature of
pediatric-onset CD [27], which manifest as poor weight
gain or short stature and may be the first presenting
symptom. We observed a trend in CD patients with
NOD2 variants towards underweight at diagnosis in our
pediatric-onset cohort analogous to other studies [28-30]
describing lower weight and a tendency to growth
retardation more or less pronounced in their pediatriccohorts. In addition, we found also significant ongoing
underweight in the course of disease in patients with
NOD2 variant alleles. Growth failure seems to be associated
with disease severity [29] and high levels of TNFα in
pediatric IBD [31]. Indeed, the average disease activity in
pediatric-onset CD patients carrying at least one NOD2
variant allele was significantly higher and associated
with chronic active or moderate to severe clinical course
of disease. However, other studies did not found an
influence of NOD2 variants towards higher disease
Figure 4 Effect of PCDAI on BMD. CD patients with pediatric-
onset are compared regarding their PCDAI and BMD z-value. The
median (lines within the boxes), the interquartile range (boxes) and
the whole range are given. Differences were compared using
Kruskal-Wallis test. The medians varies significant (*), p-value is
0.0253 using Gaussian approximation.
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Figure 5 Effect of NOD2 variant alleles on treatment in
pediatric- and adult-onset CD. CD patients with pediatric-onset
(A) or adult-onset (B) of disease with NOD2 variant (grey bars) or
NOD2 wild-type alleles (white bars) are compared regarding steroid-
dependent or refractory course of disease, need for long-term
immunosuppressive therapy with azathioprine (AZA) and methotrexate
(MTX) or anti-TNFα antibody. Differences were compared using
chi-square or Fishers exact test, respectively. A p-value below ≤0.05
was considered to be significant.
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http://www.biomedcentral.com/1471-230X/13/77activity [25,29]. This is explicable by the fact, that in
most instances disease activity was educed from
hospitalization, need for immunosuppressive drugs,
surgery or occurrence of complications but not by
PCDAI at onset and during course of disease [25,28,29,32].
The PCDAI-score was only used by one other pediatric
study with 65 CD patients, which described an influence
of NOD2 variants towards a higher PCDAI [30]. Besides
actual history and laboratory values (e.g. haematocrit,
erythrocyte sedimentation rate and albumin) the PCDAI
score includes also weight loss, growth delay, perirectal
disease and extraintestinal manifestation. Therefore a high
PCDAI score in our pediatric-onset CD patients with
NOD2 variants reflects a more severe disease behaviour
indicated by underweight, stricturing and penetrating
behaviour. Moreover, an aggressive disease manifestation
in pediatric-onset CD patients with NOD2 variants leading
to complications and surgical resection is described by
Lacher et al. [12] and Kugathasan et al. [32,33].
The prevalence of osteoporosis ranges from 7 to 30%
and osteopenia from 22 to 70% in pediatric IBD studies
[13,34,35]. In fact, 30% of our patients with pediatric-onset
CD have osteoporosis and 31% osteopenia, some even
before corticosteroid treatment confirming data from
Walther [13] and Harpavat et al. [36]. Possible risk factors
for pathologic bone density in CD are disease activity,
lifetime steroid dosage over 10 g, CD, multiple bowel
resections, young age and low body mass index
according to a large epidemiological study [37]. We also
observed low BMI and a higher disease activity associated
with reduced bone density in pediatric-onset CD. Similar
Paganelli et al. described an inversely correlation ofvolumetric BMD with disease activity measured by PCDAI
and IL-6 [38]. Other risk factors such as ileal localization
and bowel resection did not play a role in our pediatric-
onset cohort. Lifetime corticosteroid treatment in children
with IBD seems to be less important as previously believed,
as children with a chronic non-inflammatory type of
disease such as steroid sensitive nephritic syndrome
(SSNS) receiving glucocorticoids chronically do have a
better bone mineral density than children with CD [39].
Certainly osteoporosis was associated with a steroid refrac-
tory or dependent course of disease in the pediatric-onset
group. In fact the glucocorticoid dosage in the treatment
of pediatric CD may be not as high as in previous older
studies; children with CD often receive enteral nutrition
therapy and there are more patients with steroid dependent
or refractory course of disease in the low BMD group
actually switched earlier to a long-term immunosup-
pressive therapy including azathioprine, methotrexate and
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state in CD might basically contribute to high-turn over
bone mineral loss. It is also known that NOD2 variant
alleles induce an inflammatory response e.g. via NF-кB
activation [40]. Thus some cytokines with osteolytic
activity such as TNFα, IL-1β, IL-6, IFNγ, RANK,
RANKL and osteoprotegrin may also be elevated. IL-1
β for example stimulates osteoclast activity and enhances
mineral bone loss. In fact carriers of IL1β -511b allele have
significant lower BMD [41]. Interestingly, CD patients
carrying NOD2 variant alleles have an increased risk
towards osteoporosis. This is more pronounced in
pediatric-onset CD, especially in patients carrying homo-
zygous NOD2 variant alleles. However, we could not prove
our hypothesis that osteoporosis is significantly more
frequent in pediatric-onset CD patients carrying any NOD2
variant allele may be due to a lack of power. Taken
together, these data support screening of osteoporosis
in pediatric onset CD, especially in children with NOD2
variants, low BMI and high PCDAI.
We recently reported that CD patients with NOD2
carrier status were more refractory for steroid treatment
but responded well to immunomodulators such as AZA/
6-MP [42]. This was in contrast to another study that
could not find an association between NOD2 carrier status
or age of onset of disease and response to steroids [43].
We speculated that treatment response might vary analyzing
pediatric and adult CD patient study cohorts regarding
NOD2 genotype. To corroborate this hypothesis we now
included a pediatric CD cohort and reclassified all CD
patients in our adult cohort according to the onset of
disease in pediatric and adult onset. Using this approach
we found a significant association for steroid failure in CD
patients with NOD2 variant alleles and younger age of
onset in contrast to Weiss et al. [43]. In addition, the need
for long-term immunosuppressive therapy and second line
therapy with anti-TNF-alpha agents was also only associated
with younger age of onset and the presence of any
NOD2 variant allele. Although a positive response to the
anti-TNFα agent infliximab was found to be associated
with a higher systemic inflammation [44], the NOD2
genotype was not predictive of treatment outcome in their
cohort [45]. The diverging results regarding our study
cohort might be due to the subgroup analysis of
pediatric-onset CD. The fact that we did not investigate
treatment outcome is another disadvantage of this study
and its retrospective approach.
Conclusion
In summary, dissecting a large unselected group of
patients with long-term CD duration in pediatric- and
adult-onset of disease revealed a more pronounced
difference between NOD2 genotype and phenotype in the
pediatric-onset group. There was an association of NOD2gene variants towards a more affected phenotype with
underweight, higher disease activity, steroid failure and the
need for long-term and intensive immunosuppressive ther-
apy. Thus pediatric-onset CD and NOD2 variant alleles are
risk factors frequently associated with chronic and moder-
ate to severe course of disease. In addition, the prevalence
of low bone mineral density is considerably high in
pediatric Crohn patients with high average PCDAI, low
BMI, steroid failure and NOD2 variant alleles.
The major goal in the treatment of CD is to change
the fatal course of chronic active disease especially in
children and adolescents in order to improve growth
and prevent osteoporosis. Until now testing for NOD2
variants is not part of the diagnostic work-up in
pediatric-onset CD. We conclude from our study, that
genetic testing for NOD2 variant alleles is useful in
pediatric-onset CD as it may identify patients who are at
risk for a more affected phenotype. Given the beneficial
effect of TNF-α blockade on bone formation and on CD
activity this may be an alternative early treatment strategy
in children [5,46].
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